Detalles de la búsqueda
1.
The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Breast Cancer Res Treat
; 203(2): 339-349, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878148
2.
Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
Breast Cancer Res Treat
; 205(2): 287-302, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38381274
3.
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Lancet Oncol
; 24(7): 757-771, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37329889
4.
Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.
Breast Cancer Res Treat
; 198(2): 239-251, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36635428
5.
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
BMC Cancer
; 23(1): 205, 2023 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36870947
6.
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Int J Cancer
; 150(1): 124-131, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34460112
7.
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
Breast Cancer Res Treat
; 192(2): 331-342, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35025003
8.
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Breast Cancer Res Treat
; 188(2): 571-581, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743103
9.
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Breast Cancer Res Treat
; 179(3): 677-685, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31782032
10.
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
Breast Cancer Res Treat
; 180(3): 675-685, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32124136
11.
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Acta Oncol
; 59(6): 713-722, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32141389
12.
An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
Acta Oncol
; 59(9): 1123-1130, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32544366
13.
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Int J Cancer
; 145(5): 1325-1333, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30748011
14.
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Int J Cancer
; 145(1): 274-283, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30588619
15.
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 167(3): 659-669, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29058175
16.
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Breast Cancer Res Treat
; 172(2): 413-423, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121808
17.
Four-year effects of exercise on fatigue and physical activity in patients with cancer.
BMC Med
; 16(1): 86, 2018 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29879968
18.
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Lancet Oncol
; 18(11): 1502-1511, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29031778
19.
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Acta Oncol
; 61(5): 619-624, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139727
20.
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Cancer
; 122(19): 2961-70, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27315546